AlertEdge.io
Single-Ticker Trade Brief
CVS — CVS Health Report Date: 2026-10-15 20:36 UTC  |  Sector: Health Care  |  Rating:
RISK DISCLAIMER: This is an automated breakout signal. Always validate before entering a position.
▲ Breakout Signal — Volume Confirmed

CVS closed above the $92.24 breakout level on 1.26x average volume. ATR-based levels set automatically. Next resistance target: $96.59.

Ticker
CVS
Entry Price
$92.56
Breakout Level
$92.24
Stop Loss
$90.23
TP1 Target
$96.59
TP2 Target
$99.28
Risk / Reward
1 : 1.72
1.26x avg volume
View CVS Chart on TradingView

Key Price Levels

TP1 Target
$96.59
Breakout Level
$92.24
Entry
$92.56
Stop Loss
$90.23

Fundamentals

P/E Ratio
N/A
EPS (TTM)
N/A
Dividend Yield
0%
52-Wk High
N/A
52-Wk Low
N/A
Beta
N/A

Deep Dive Analysis — Claude Sonnet

ALERTEDGE TRADE BRIEF — CVS Health (CVS)

Generated by AlertEdge.io

SETUP

CVS is pushing above the $92.24 breakout level with the session closing near the high of the bar at $92.61, suggesting buyers are in control into the close. The candle structure shows a tight range with a higher low at $91.91, which is constructive. Volume is running at 1.26x average — enough to confirm participation but not a strong surge. The move from open to close is directional and clean. TP1 at $96.59 offers roughly 4% upside before the next decision point, with TP2 at $99.28 representing a potential return to the psychological $100 zone.

CATALYSTS

CVS operates across pharmacy benefits, retail health, and insurance through Aetna, making it sensitive to Medicare Advantage policy shifts and broader healthcare reform narratives. The sector has seen rotation interest as defensive positioning picks up during macro uncertainty. Any positive development around cost management, Oak Street Health integration progress, or Aetna membership stabilization could accelerate this move. Watch for any upcoming earnings date or CMS reimbursement announcements — these are the real binary events for CVS.

RISKS

Fundamental data is missing entirely — no P/E, no EPS, no 52-week range. This is a significant blind spot. CVS has been navigating elevated debt loads from its Aetna acquisition and has faced pressure on pharmacy margins and insurance cost ratios. If earnings or guidance disappoint, this breakout fails quickly. The stop at $90.23 represents a $2.33 risk per share — reasonable structurally, but a gap down on bad news would slice through it. The signal quality score of 50 out of 100 is mediocre and should not be ignored. No news catalyst is confirmed, which means this is a purely technical play with no fundamental ignition behind it.

CONVICTION: Low

The missing fundamental data combined with a weak 50/100 signal quality score and absence of any confirmed catalyst makes this a technically marginal setup with too many unknowns to size aggressively.